K34c
Based on 1 Customer Validation
K34c is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c can be used in glioblastoma research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.79%
- CAS 番号: 939769-93-4
- 分子式: C26H29N3O4
- 分子量:447.53
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
生物活性
製品説明
IC50 & Target
[1]|
α5β1 |
体外実験
K34c (20 μM; 24 or 48 h) significantly induces U87MG cells apoptosis in combination with 1 μM Ellipticine (HY-15753)[1].
K34c (20 μM; 48 h) significantly decreases Temozolomide (HY-17364)-induced senescence in cells transfected with control non targeting siRNA without affecting significantly the residual senescence of cells transfected with siRNA specific for p53[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87MG cells
-
Concentration:20 μM
-
Incubation Time:24 or 48 h
-
Result:Induced apoptosis, led to a significant increase in apoptotic cell death measured by the population of sub-G1 cells in combination with 1 μM Ellipticine (HY-15753).
-
Cell Line:U87MG cells
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Decreased Ellipticine (HY-15753)- and Temozolomide (HY-17364)-induced activation of p53.
化学情報
-
CAS 番号 939769-93-4
-
性状 Solid
-
分子量 447.53
-
分子式 C26H29N3O4
-
Color White to off-white
-
SMILES
O=C(O)[C@H](CC1=CC=C(OCCCNC2=NC=CC=C2)C=C1)NC(C3=C(C)C=CC=C3C)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 125 mg/mL (279.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2345 mL | 11.1724 mL | 22.3449 mL | 55.8622 mL |
| 5 mM | 0.4469 mL | 2.2345 mL | 4.4690 mL | 11.1724 mL | |
| 10 mM | 0.2234 mL | 1.1172 mL | 2.2345 mL | 5.5862 mL | |
| 15 mM | 0.1490 mL | 0.7448 mL | 1.4897 mL | 3.7241 mL | |
| 20 mM | 0.1117 mL | 0.5586 mL | 1.1172 mL | 2.7931 mL | |
| 25 mM | 0.0894 mL | 0.4469 mL | 0.8938 mL | 2.2345 mL | |
| 30 mM | 0.0745 mL | 0.3724 mL | 0.7448 mL | 1.8621 mL | |
| 40 mM | 0.0559 mL | 0.2793 mL | 0.5586 mL | 1.3966 mL | |
| 50 mM | 0.0447 mL | 0.2234 mL | 0.4469 mL | 1.1172 mL | |
| 60 mM | 0.0372 mL | 0.1862 mL | 0.3724 mL | 0.9310 mL | |
| 80 mM | 0.0279 mL | 0.1397 mL | 0.2793 mL | 0.6983 mL | |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2234 mL | 0.5586 mL |